ENTRY       D10559                      Drug
NAME        Dinutuximab (USAN/INN);
            Dinutuximab (genetical recombination) (JAN);
            Unituxin (TN)
PRODUCT     UNITUXIN (United Therapeutics Corporation)
SEQUENCE    (Heavy chain)
            EVQLLQSGPE LEKPGASVMI SCKASGSSFT GYNMNWVRQN IGKSLEWIGA IDPYYGGTSY
            NQKFKGRATL TVDKSSSTAY MHLKSLTSED SAVYYCVSGM EYWGQGTSVT VSSASTKGPS
            VFPLAPSSKS TSGGTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS
            VVTVPSSSLG TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP
            PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS
            VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS
            LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
            CSVMHEALHN HYTQKSLSLS PGK
            (Light chain)
            EIVMTQSPAT LSVSPGERAT LSCRSSQSLV HRNGNTYLHW YLQKPGQSPK LLIHKVSNRF
            SGVPDRFSGS GSGTDFTLKI SRVEAEDLGV YFCSQSTHVP PLTFGAGTKL ELKRTVAAPS
            VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS
            LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
            (Disulfide bridge: H22-H96, H140-H196, H216-L220, H222-H'222, H225-H'225, H257-H317, H363-H421, H'22-H'96, H'140-H'196, H'216-L'220, H'257-H'317, H'363-H'421, L23-L93, L140-L200, L'23-L'93, L'140-L'200)
  TYPE      Peptide
REMARK      Therapeutic category: 4291
            ATC code: L01FX06
            Product: D10559<JP/US>
EFFICACY    Antineoplastic, Immunomodulator, Anti-GD2 antibody
  DISEASE   Neuroblastoma [DS:H02301]
  TYPE      Monoclonal antibody
TARGET      GD2 [GL:G00114]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX06 Dinutuximab beta
                  D10559  Dinutuximab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Dinutuximab
                D10559  Dinutuximab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10559  Dinutuximab (USAN/INN); Dinutuximab (genetical recombination) (JAN)
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10559
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10559
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10559
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10559
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10559
DBLINKS     CAS: 1363687-32-4
            PubChem: 254741521
///
